The TIMI Study Group   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1984)

Organization Overview

First Clinical Trial
2004
NCT00099788
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

The TIMI Study Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Atherosclerosis (Phase 3)

Atrial Fibrillation (Phase 3)

Cardiovascular Diseases (Phase 3)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Embolism (Phase 3)

Heart Failure (Phase 4)

Infarction (Phase 4)

Ischemia (Phase 3)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 3)

Syndrome (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Venous Thromboembolism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 16